CASE STUDY: INSIGHTS INTO ANTICOAGULATION USE IN CARDIOVERSION OR ABLATION
Our client wanted to get a deeper understanding of the use of anticoagulation, in particular, the use of NOACs in atrial fibrillation (AF) patients who undergo cardioversion or ablation in Nordics, UK, France, Italy, Germany and Spain. Our client wanted to determine the reasons behind the drugs choice, usage and switch. Therefore, they needed to get the physicians insights on the treatment and management of the patients, as well as reimbursement landscape in each of the markets.
Our approach included the quantitative (online) primary research methodology to answer the client objectives. The sample in all the researched markets consisted of physicians using NOACs in AF patients undergoing cardioversion and ablation: cardiologists, interventional cardiologists and electrophysiologists.
To ensure the quality and consistency of the data the survey was translated in the local languages. We also initiated a first round of exploratory pilot interviews with a small number of participants in each market, before proceeding with the full launch.
AF Patients Undergoing Cardioversion and Ablation that Were Prescribed NOACs in 2015
The client received a rounded overview of the NOCS usage in the patients that undergo cardioversion and ablation. This included patients management pathway, current NOCAs usage trends, factors influencing NOACs choice, insight into the NOAC timelines around cardioversion and ablation, rationale behind switching the from one NOAC to another during the treatment, as well as reimbursement in the researched markets.